Wells Fargo analyst Yanan Zhu thinks today’s data from Dyne Therapeutics’ (DYN) from its trial of DYNE-101 in patients with myotonic dystrophy type 1 cross-validate Avidity Biosciences’ (RNA) observation of myotonia benefit at six months. Dyne’s data could help contextualize and validate what Avidity observed in its myotonic dystrophy type 1 study, the analyst tells investors in a research note. The firm now expects increased confidence in Avidity’s prior date and outlook for AOC1001. It keeps an Overweight rating on the shares with a $50 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RNA:
- M & A News: Bristol-Myers Squibb (NYSE:BMY) to Buy RayzeBio for $4.1B
- Avidity Biosciences announces data from Phase 1/2 EXPLORE44 clinical trial
- Biotech Alert: Searches spiking for these stocks today
- Bristol-Myers (NYSE:BMY) Expands Collaboration with Avidity Bio in $2.3B Deal
- Avidity Biosciences expands cardiovascular collaboration with Bristol Myers